Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other 1

Conditions

Obesity 9Endometrial Neoplasms 3Overweight 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Metabolic Syndrome 1Insulin Resistance 1Inflammation 1Hyperplasia 1Endometrial Hyperplasia 1Dyslipidemias 1Diabetes Mellitus 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

semaglutide 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1Topiramate 1Tirzepatide 1Testosterone 1Qsymia 1Phentermine 1Pancreaticoduodenectomy 1Naltrexone 1Medical History Taking 1Magnetic Resonance Spectroscopy 1Liraglutide 1Hepatectomy 1Hematologic Tests 1Gonadotropin-Releasing Hormone 1Glucagon-Like Peptide-1 Receptor 1Diethylpropion 1Diathermy 1Colonoscopy 1Bupropion 1Blood Pressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metabolic Syndrome × Tirzepatide × Other × Clear all
NCT05756764 2025-09-09

Anti-obesity Pharmacotherapy and Inflammation

Louisiana State University Health Sciences Center in New Orleans

Active not recruiting
30 enrolled
Other

Inflammation, Obesity, Metabolic Syndrome, Dyslipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡